Physician profile
Cheryl Tierney
NPI 1023092749
$2,420.38
in general payments reported to CMS, 2019-2025
2 companies · $2,273 in 2025
The $2,273 reported for 2025 was more than what 93% of Developmental - Behavioral Pediatrics providers received nationally (typical 2025 total: $79.84).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $148 · 2025: $2,273.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,845 · Food and Beverage: $575.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,845.00 |
| Food and Beverage | $575.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Earlitec Diagnostics INC. | $1,845.00 | 2025 | |
| Supernus Pharmaceuticals, INC. | $575.38 | 2024-2025 | Qelbree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cheryl Tierney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.